טוען...
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia
Eltrombopag, an oral thrombopoietin receptor agonist, is dosed daily to treat chronic immune thrombocytopenia (ITP). As it has a half‐life of 26–35 h in ITP patients and requires patents to abide by strict dietary restrictions that may impair quality of life and reduce compliance, we developed an al...
שמור ב:
| הוצא לאור ב: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6177710/ https://ncbi.nlm.nih.gov/pubmed/30032487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13717 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|